OWC Pharmaceutical to Discuss Cannabis-based Therapies at Monaco Event

OWC Pharmaceutical to Discuss Cannabis-based Therapies at Monaco Event

OWC Pharmaceutical Research will give a presentation in Monaco next week on cannabis-based therapies, which studies have shown help people with fibromyalgia, psoriasis and other inflammatory conditions.

Yehuda Baruch, the company’s chief science officer, will talk about “Cannabis And The Endocannabinoid System: A New And Emerging Pipeline For Medical Products,” at the Monaco Growth Forums Spring Edition, April 25-26.

A key aim is to create interest in cannabis-based therapies in Europe, the company acknowledged.

Cannabis-based treatments have been gaining momentum as a valuable option across a growing range of diseases, including fibromyalgia, psoriasis, multiple myeloma, and migraine headaches. OWC is working on appropriate doses and delivery systems for medical cannabis.

Cannabidiol, the plant’s pure molecular compound, has anti-inflammatory and pain-relieving properties, and no known psycho-active effects. Research has shown that cannabidiol can be an effective treatment for many types of pain, particularly inflammatory pain.

Among those who benefit from cannabis pain relief are fibromyalgia patients, studies have shown. One testament to the treatment was an online survey of more than 1,300 fibromyalgia patients in 2016. Many respondents said cannabis did a better job of treating their symptoms than therapies that the U.S. Food and Drug Administration (FDA) has approved.

A clinical trial has shown that a cannabinoid-based therapy also reduced inflammatory markers in psoriasis. The results suggested it could be used against other inflammation-related disorders.

“We are very excited to participate in this prestigious European event, and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ [medical marijuana] clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first,” Mordechai Bignitz, the CEO of OWC, said in a news release. “We anticipate that together with some states in the U.S. and Canada, Europe can soon become a primary market for our products.”

Andreea Porcelli, CEO of Monaco Growth Forums, added: “We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area.”

2 comments

  1. Mix Rita says:

    It would be interesting to see the results of a more significant study of 50,000 sufferers and then tackle the government for approval to dispense fibromyalgia patients.

Leave a Comment

Your email address will not be published. Required fields are marked *